Trial Profile
Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix-IPV/Hib) in Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Hib-DTaP-poliovirus vaccine (Primary)
- Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
- Focus Adverse reactions; Registrational
- Sponsors GlaxoSmithKline; GSK
- 04 Feb 2011 Trial phase changed from I to III as reported by ClinicalTrials.gov.
- 27 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.